CR9828A - Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa - Google Patents

Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa

Info

Publication number
CR9828A
CR9828A CR9828A CR9828A CR9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
new mode
cyclooxygenase enzyme
modified
cyclooxygenase
Prior art date
Application number
CR9828A
Other languages
English (en)
Inventor
Jain Rajesh
Chand Jindal Kour
Singh Sukhjeet
Talwar Munish
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR9828A publication Critical patent/CR9828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se provee una presentacion farmaceutica de liberacion modificada que comprende al menos un inhibidor de la enzima ciclooxigenasa o sus sales, esteres, profarmacos, solvatos, hidratos o derivados farmaceuticamente aceptables como agente activo, con un portador farmceuticamente aceptable para controlar la liberacion del inhibidor de enzima ciclooxigenasa.
CR9828A 2005-07-20 2008-03-26 Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa CR9828A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1899DE2005 2005-07-20

Publications (1)

Publication Number Publication Date
CR9828A true CR9828A (es) 2008-07-31

Family

ID=37669241

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9828A CR9828A (es) 2005-07-20 2008-03-26 Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa

Country Status (20)

Country Link
US (1) US20100204333A1 (es)
EP (1) EP1906933A2 (es)
JP (1) JP2009501785A (es)
KR (1) KR20080032209A (es)
CN (1) CN101227893A (es)
AR (1) AR055090A1 (es)
AU (1) AU2006271150A1 (es)
BR (1) BRPI0613547A2 (es)
CA (1) CA2614850A1 (es)
CR (1) CR9828A (es)
DE (1) DE202006020331U1 (es)
DK (1) DK200900115U1 (es)
EA (1) EA200800370A1 (es)
MX (1) MX2008000967A (es)
NO (1) NO20080697L (es)
RS (1) RS20080020A (es)
TN (1) TNSN08018A1 (es)
UA (1) UA89684C2 (es)
WO (1) WO2007010559A2 (es)
ZA (1) ZA200801592B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649620A1 (en) * 2006-04-24 2007-11-01 Panacea Biotec Ltd. Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8546450B1 (en) * 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
CN102188386B (zh) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 尼美舒利缓释微丸及其制备方法
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR20180025993A (ko) * 2012-01-04 2018-03-09 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
US9642824B2 (en) 2012-02-06 2017-05-09 Innovative Med Concepts, LLC Valaciclovir and diclofenac combination therapy for functional somatic syndromes
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
IN188720B (es) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU718356B2 (en) * 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
AU5134699A (en) * 1998-07-24 2000-02-14 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
WO2000015195A1 (en) 1998-09-10 2000-03-23 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
RS50303B (sr) * 1999-09-28 2009-09-08 Panacea Biotec Limited, Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
IN190018B (es) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
US20020015735A1 (en) * 1999-12-22 2002-02-07 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
IN190963B (es) * 2000-06-20 2003-09-06 Ajanta Pharma Ltd
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone

Also Published As

Publication number Publication date
WO2007010559A2 (en) 2007-01-25
ZA200801592B (en) 2009-10-28
US20100204333A1 (en) 2010-08-12
TNSN08018A1 (en) 2009-07-14
MX2008000967A (es) 2008-03-26
UA89684C2 (ru) 2010-02-25
DE202006020331U1 (de) 2008-09-18
KR20080032209A (ko) 2008-04-14
NO20080697L (no) 2008-04-18
EP1906933A2 (en) 2008-04-09
CA2614850A1 (en) 2007-01-25
EA200800370A1 (ru) 2008-06-30
AR055090A1 (es) 2007-08-08
JP2009501785A (ja) 2009-01-22
BRPI0613547A2 (pt) 2011-01-18
WO2007010559A3 (en) 2007-09-20
RS20080020A (en) 2009-05-06
DK200900115U1 (en) 2009-10-23
AU2006271150A1 (en) 2007-01-25
CN101227893A (zh) 2008-07-23

Similar Documents

Publication Publication Date Title
CR9828A (es) Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR083417A1 (es) Composiciones farmaceuticas que contienen un dgat1 inhibidor
CR11499A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
BRPI0821255A2 (pt) Derivados de espiroindolinona
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
CR20170159A (es) Nuevos compuestos tricíclicos
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
DOP2006000170A (es) Nuevos derivados de espirocromanona
HN2009000968A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
UY32045A (es) Compuesto amida
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
BRPI0709769B8 (pt) implantes biodegradáveis para o tratamento de estados associados à dopamina
ECSP10010167A (es) Composiciones oftálmicas novedosas
RS53586B1 (en) DERIVATION OF DECISION
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
AR072235A1 (es) Proceso enzimatico para obtener 17-alfa monoesteres de cortexolona y/o sus 9,11-dehidro derivados
UY32299A (es) Composiciones farmacéuticas líquidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)